Status:
COMPLETED
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
Lead Sponsor:
AstraZeneca
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.
Eligibility Criteria
Inclusion
- Confirmation of metastatic or recurrent renal cell carcinoma
Exclusion
- Certain types of previous anti-cancer therapy for Renal Cell Carcinoma
- Patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-independent diabetes
- Patients with a history of poorly controlled high blood pressure
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00423332
Start Date
January 1 2007
End Date
October 1 2016
Last Update
February 2 2017
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Groningen, Netherlands
2
Research Site
Leiden, Netherlands
3
Research Site
Nijmegen, Netherlands
4
Research Site
Birmingham, United Kingdom